Drug Profile


Alternative Names: DF01

Latest Information Update: 15 Oct 2015

Price : $50

At a glance

  • Originator Dilafor
  • Developer Dilafor; Lees Pharmaceutical Holdings
  • Class Glycosaminoglycans; Low molecular weight heparins
  • Mechanism of Action Muscle protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Dystocia

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 25 Jul 2015 Dilafor completes a phase I trial in Dystocia (In volunteers) in Sweden
  • 25 Jul 2015 Dilafor plans a phase II trial for Dystocia in China and a phase I trial in Asian subjects
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top